Pulse Biosciences, Inc.

NasdaqCM PLSE

Pulse Biosciences, Inc. Market Capitalization on January 14, 2025: USD 1.06 B

Pulse Biosciences, Inc. Market Capitalization is USD 1.06 B on January 14, 2025, a 131.32% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Pulse Biosciences, Inc. 52-week high Market Capitalization is USD 1.37 B on December 04, 2024, which is 29.21% above the current Market Capitalization.
Pulse Biosciences, Inc. 52-week low Market Capitalization is USD 371.82 M on April 25, 2024, which is -64.86% below the current Market Capitalization.
Pulse Biosciences, Inc. average Market Capitalization for the last 52 weeks is USD 792.37 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: PLSE

Pulse Biosciences, Inc.

CEO	Mr. Robert W. Duggan
IPO Date	May 18, 2016
Location	United States
Headquarters	3957 Point Eden Way
Employees	56
Sector	Health Care
Industries Biotechnology Energy Storage & Batteries Pharmaceuticals

Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Key trends

Past 5 years